Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

QL1706 Combined With PE Compared With PE for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer

NCT06967103 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT06967103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06967103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
QL1706 Combined With PE Compared With PE for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer
Lead sponsor
Henan Cancer Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
September 8, 2025
Completion date
May 30, 2029
Enrollment
238 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, hr+/her2- breast cancer